Revisión

Antidepressants in epilepsy

B. Castaño-Monsalve [REV NEUROL 2013;57:117-122] PMID: 23881616 DOI: https://doi.org/10.33588/rn.5703.2013192

OPEN ACCESS

Volumen 57 | Number 03 | Nº of views of the article 15.259 | Nº of PDF downloads 1.348 | Article publication date 01/08/2013

Download PDF Castellano Citation Search in PubMed

Share in:

Go to another issue

ABSTRACT

Depression is a common condition in patients with epilepsy that entails a deterioration of the quality of life of this population and that, therefore, requires appropriate treatment. The potential risk of antidepressants in relation to the seizure threshold is overestimated by many professionals, and this has an influence when it comes to making the decision to treat them. It sometimes means that the patients do not receive antidepressant drugs. In this regard, the aim of this review is to present the current state of the art in terms of the safety of antidepressants in patients with epilepsy. A search of the medical literature was conducted and, following its analysis, the most significant results are presented. Current information indicates that most antidepressants are safe for epileptic patients at therapeutic doses and that the risk of seizures occurs mainly in cases of overdose. Preferred drugs for treating depression in epilepsy are serotonin reuptake inhibitors. Bupropion and tricyclic antidepressants must be avoided. KeywordsAntidepressants Depression Epilepsy Seizures Selective serotonin reuptake inhibitors CategoriesEpilepsias y síndromes epilépticos Neuropsiquiatría

FULL TEXT (solo disponible en lengua castellana / Only available in Spanish)

Acceso directo al último número

Último Podcast

Revisión

Antidepressants in epilepsy

¡CONVIÉRTASE EN USUARIO PREMIUM DE NEUROLOGIA.COM!

Al hacerse premium, está apoyándonos para que Revista de Neurología siga siendo uno de los referentes de habla hispana en la difusión del conocimiento en neurociencias. ¡Gratuita tanto para autores como para todos los usuarios de la web!